Altium Capital Management LLC Sells 377,631 Shares of ESSA Pharma Inc. (NASDAQ:EPIX)

Key Points

• Altium Capital Management LLC reduced its stake in ESSA Pharma Inc. by 26.4%, now holding approximately 1,050,369 shares valued at $1,660,000.
• Other institutional investors, including Bank of America and BNP Paribas Financial Markets, have significantly increased their positions in ESSA Pharma during the fourth quarter.
• ESSA Pharma's stock currently trades at $1.91, with a market cap of $84.78 million and a 52-week range between $1.40 and $7.88.

Altium Capital Management LLC trimmed its position in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 26.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,050,369 shares of the company's stock after selling 377,631 shares during the period. ESSA Pharma makes up about 4.0% of Altium Capital Management LLC's portfolio, making the stock its 8th largest holding. Altium Capital Management LLC owned 2.37% of ESSA Pharma worth $1,660,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Deuterium Capital Management LLC acquired a new stake in ESSA Pharma in the first quarter worth approximately $174,000. GTS Securities LLC acquired a new stake in shares of ESSA Pharma during the 4th quarter valued at $30,000. Squarepoint Ops LLC acquired a new stake in shares of ESSA Pharma during the 4th quarter valued at $26,000. Two Sigma Advisers LP acquired a new stake in shares of ESSA Pharma during the 4th quarter valued at $148,000. Finally, Two Sigma Investments LP acquired a new stake in shares of ESSA Pharma during the 4th quarter valued at $378,000. 75.12% of the stock is currently owned by institutional investors and hedge funds.

ESSA Pharma Price Performance

Shares of NASDAQ:EPIX traded up $0.01 on Friday, reaching $1.93. 217,663 shares of the company traded hands, compared to its average volume of 310,125. ESSA Pharma Inc. has a fifty-two week low of $1.40 and a fifty-two week high of $7.88. The company's 50 day moving average is $1.80 and its 200-day moving average is $1.71. The stock has a market capitalization of $91.31 million, a PE ratio of -3.45 and a beta of 1.55.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08. As a group, analysts expect that ESSA Pharma Inc. will post -0.42 EPS for the current year.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.